Under the Control Substances Act (“CSA”), marijuana is currently scheduled as an “I” drug. In a classification of “V” schedules, “I” is considered the most dangerous because it is deemed to have a “high potential for abuse” and “no medical value.” It ranks alongside other substances such as heroin and phencyclidine (“PCP”), thereby signifying that the federal government considers marijuana more dangerous than cocaine (Schedule II) and Xanax (Schedule IV).
The market for cannabis and CBD products in Germany will initially start in 2021 relatively unchanged compared to the conditions at the end of last year.
On January 7th of 2014 through Laws N° 19.172, Uruguay became one of first countries of Latin America to allow and regulate the use of recreational cannabis and for medical and research purpose. In this sense the Government create a legal framework for cannabis by creating the Laws N° 19.172 and modifying the Law N° 14.294 knows as the Narcotics Law.
As we approach the second anniversary of the historic amendment of the Thai Narcotics Act to allow the use of cannabis for medical purposes for the very first time in Thailand, the first country in Southeast Asia to do so, we take this opportunity to assess and forecast the outlook for the cannabis industry in Thailand and the region.
Plaintiffs’ attorneys across the country are seizing the opportunity to sink their teeth into the vulnerabilities faced by unregulated CBD companies by hitting them with class action lawsuits. The FDA and FTC provide additional fodder through their enforcement actions. CBD companies are using the FDA’s lack of direction to their advantage to pause the crescendo of lawsuits against them for now.